Results of a recent study show that consumers generally prefer new drugs over older drugs, without fully understanding the newer drugs' risks and benefits. These findings demonstrate that the FDA's efforts to inform the public about its approval process are insufficient. "This study confirms that the public lacks understanding of what FDA approval constitutes," pharma industry consultant Wayne Pines noted. Industry can play a role in consumer education as well, according to Peter Pitts, president and co-founder of the Center for Medicine in the Public Interest. Read more.